Research programme: cyclin-dependent kinase inhibitors - BanyuAlternative Names: cyclin-dependent kinase inhibitors research programme - Banyu
Latest Information Update: 12 Feb 2008
At a glance
- Originator Banyu
- Mechanism of Action Cyclin-dependent kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Sep 2004 No development reported - Preclinical for Cancer in Japan (unspecified route)
- 19 Sep 2001 Preclinical development for Cancer in Japan (Unknown route)